Endothelium is the main target of coronavirus infection
BACKGROUND. The world currently has a huge clinical experience in the treatment of SARS-CoV-2 infection. However, emerging scientific data opens up new information on the manifestations of coronavirus disease (COVID-19) and its consequences, which can affect both the changes of its clinical picture and the quality of patients’ life.
OBJECTIVE. To summarize the results of literature search and own experience of intensive care of endothelial dysfunction in COVID-19.
MATERIALS AND METHODS. The work is based on the results of an internet search with a help of Google and PubMed using the following key words: “intensive care of SARS-CoV-2”, “pathophysiological changes in coronavirus infection”, and “endothelial dysfunction”.
RESULTS. This review describes the links of COVID-19 pathogenesis, mechanisms of viral endothelial damage and hypercoagulopathy, and the main directions of prevention and treatment of endothelial dysfunction.
CONCLUSIONS. SARS-CoV-2 infection promotes endotheliitis in various organs as a result of viral infection. The presence of COVID-19-induced endotheliitis can explain the systemic microcirculation disorders in various vascular beds and their clinical consequences.
Ackermann M., Verleden S.E., Kuehnel M., et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N. Engl. J. Med. 2020; 383 (2): 120-128.
Fox S.E., Akmatbekov A., Harbert J.L., et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir. Med. 2020; 8 (7): 681-686.
Tang N., Li D., Wang X., et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020; 18 (4): 844-847.
Leppkes M., Knopf J., Naschberger E., et al. Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine. 2020; 58: 102925.
Gando S., Wada T. Thromboplasminflammation in COVID-19 coagulopathy: three viewpoints for diagnostic and therapeutic strategies. Front. Immunol. 2021; 12: 649122.
Karpov Yu.A. Endoteliy – novaya mishen dlya lechebnogo deystviya ingibitorov angiotenzinprevrashchayushchego fermenta [Endothelium is a new target for the therapeutic action of angiotensin-converting enzyme inhibitors]. Terapevticheskiy arkhiv. 2004; 76 (6): 94-96.6.
Ji H.-L., Zhao R., Matalon S., et al. Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility. Physiol. Rev. 2020; 100 (3): 1065-1075.
Magro C., Mulvey J.J., Berlin D., et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl. Res. 2020; 220: 1-13.
Yang X., Yang Q., Wang Y., et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J. Thromb. Haemost. 2020; 18 (6): 1469-1472.
Lippi G., Plebani M., Henry B.M. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin. Chim. Acta. 2020; 506: 145-148.
Zhang L., Yan X., Fan Q., et al. D-dimer levels on admission to predict in-hospital mortality in patients with COVID-19. J. Thromb. Haemost. 2020; 18 (6): 1324-1329.
Abelardejo P. Expert review of anti-infective therapy. DOI: 10.1080/14787210.2020.1808462.
Helms J., Tacquard C., Severac F., et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020; 46 (6): 1089-1098.
Mizurini D.M., Hottz E.D., Bozza P.T., et al. Fundamentals in COVID-19- associated thrombosis: molecular and cellular aspects. Front. Cardiovasc. Med. 2021; 8: 785738.
Roncon L., Zuin M., Barco S., et al. Incidence of acute pulmonary embolism in COVID-19 patients: systematic review and meta-analysis. Eur. J. Intern. Med. 2020; 82: 29-37.
Poissy J., Goutay J., Caplan M., et al. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation. 2020; 142 (2): 184-186.
Arachchillage D.R.J., Laffan M. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020; 18 (5): 1233-1234.
Connors J.M., Levy J.H. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020; 135 (23): 2033-2040.
Prevention and management of venous thromboembolism in COVID-19 (A Rapid National Clinical Guideline). Available at: https://www.sign.ac.uk/media/1893/20210915-prevention-and-management-of-thromboembolism-peer-review-draft.pdf.
Susen S., Tacquard C.A., Godon A., et al. Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Critical Care. 2020; 24: 364.
White D., MacDonald S., Bull T. Heparin resistance in COVID-19 patients in the intensive care unit. J. Thromb. Thrombolysis. 2020; 50 (2): 287-291.
Adebayo A., Varzideh F., Wilson S., et al. L-arginine and COVID-19: an update. Nutrients. 2021; 13 (11): 3951.
Szefel J., Danielak A., Kruszewski W.J. Metabolic pathways of L-arginine and therapeutic consequences in tumors. Adv. Med. Sci. 2019; 64: 104-110.
Geiger R., Rieckmann J.C., Wolf T., et al. L-arginine modulates T-cell metabolism and enhances survival and anti-tumor activity. Cell. 2016; 167: 829-842.
Uhel F., Azzaoui I., Gregoire M., et al. Early expansion of circulating granulocytic myeloid-derived suppressor cells predicts development of nosocomial infections in patients with sepsis. Am. J. Respir. Crit. Care Med. 2017; 196: 315-327.
Tepaske R., Velthuis H., Oudemans-van Straaten H.M., et al. Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial. Lancet. 2001; 358: 696-701.
Zhu X., Pribis J.P., Rodriguez P.C., et al. The central role of arginine catabolism in T-cell dysfunction and increased susceptibility to infection after physical injury. Ann. Surg. 2014; 259: 171-178.
Bronte V., Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 2005; 5: 641-654.
Falck-Jones S., Vangeti S., Yu M., et al. Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity. J. Clin. Investig. 2021; 131: e144734.
Dean M.J., Ochoa J.B., Sanchez-Pino M.D., et al. Severe COVID-19 is characterized by an impaired type I interferon response and elevated levels of arginase producing granulocytic myeloid derived suppressor cells. Front. Immunol. 2021; 12: 695972.
Rees C.A., Rostad C.A., Mantus G., et al. Altered amino acid profile in patients with SARS-CoV-2 infection. Proc. Natl. Acad. Sci. USA. 2021; 118 (25): e2101708118.
Sacchi A., Grassi G., Notari S., et al. Expansion of myeloid derived suppressor cells contributes to platelet activation by L-arginine deprivation during SARS-CoV-2 infection. Cells. 2021; 10: 2111.
Grimes J.M., Khan S., Badeaux M., et al. Arginine depletion as a therapeutic approach for patients with COVID-19. Int. J. Infect. Dis. 2021; 102: 566-570.
Liao S.Y., Linderholm A., Showalter M.R., et al. L-arginine as a potential GLP-1-mediated immunomodulator of Th17-related cytokines in people with obesity and asthma. Obes. Sci. Pract. 2021; 7: 339-345.
Thomassen M.J., Buhrow L.T., Connors M.J., et al. Nitric oxide inhibits inflammatory cytokine production by human alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 1997; 17: 279-283.
This work is licensed under a Creative Commons Attribution 4.0 International License.